Cytek Biosciences (CTKB)
(Real Time Quote from BATS)
$5.25 USD
+0.11 (2.14%)
Updated Oct 18, 2024 10:12 AM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Cytek Biosciences, Inc. (CTKB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$8.70 | $10.00 | $7.50 | 69.26% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Cytek Biosciences, Inc. comes to $8.70. The forecasts range from a low of $7.50 to a high of $10.00. The average price target represents an increase of 69.26% from the last closing price of $5.14.
Analyst Price Targets (5 )
Broker Rating
Cytek Biosciences, Inc. currently has an average brokerage recommendation (ABR) of 1.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.67 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, four are Strong Buy, representing 66.67% of all recommendations. A month ago, Strong Buy represented 66.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.67 | 1.67 | 1.67 | 1.67 | 1.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/23/2024 | Cowen & Co. | Brendan Smith | Not Available | Strong Buy |
8/13/2024 | Raymond James | Andrew Cooper | Hold | Hold |
8/7/2024 | Piper Sandler | David M Westenberg | Strong Buy | Strong Buy |
8/1/2024 | Stephens | Mason Carrico | Strong Buy | Strong Buy |
2/29/2024 | Goldman Sachs | Matthew Sykes | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.67 |
ABR (Last week) | 1.67 |
# of Recs in ABR | 6 |
Average Target Price | $8.70 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 88 of 252 |
Current Quarter EPS Est: | -0.01 |
CTKB FAQs
Cytek Biosciences, Inc. (CTKB) currently has an average brokerage recommendation (ABR) of 1.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 6 brokerage firms.
The average price target for Cytek Biosciences, Inc. (CTKB) is $8.70. The current on short-term price targets is based on 2 reports.
The forecasts for Cytek Biosciences, Inc. (CTKB) range from a low of $7.5 to a high of $10. The average price target represents a increase of $69.26 from the last closing price of $5.14.
The current UPSIDE for Cytek Biosciences, Inc. (CTKB) is 69.26%
Based on short-term price targets offered by five analysts, the average price target for Cytek Biosciences, Inc. comes to $8.70. The forecasts range from a low of $7.50 to a high of $10.00. The average price target represents an increase of 69.26% from the last closing price of $5.14.